All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD99 chimeric antigen receptor (CAR) is constructed for the engineering of T cell to target CD99. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD99 antibody linked to 4-1BB (CD137) and CD3ζ signaling domains. And the vector product was designed for the treatment of Glioma.
CAR Construction : 12E7-CD28-41BB-CD3ζ Fig.1 Expansion of CAR-T cell. Expansion fold change of CAR positive cells for 12 days. Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., ... & Zhu, H. (2021). CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of hematology & oncology, 14(1), 1-5. |
CAR Construction : 12E7-CD28-41BB-CD3ζ Fig.2 Anti-CD99 CAR T cells showed specifically target the T-ALL cell lines and primary cells but with minimal killing of normal blood cells. In vitro cytotoxic activity of anti-CD99 CAR T cells against different normal blood cells (top picture), T-ALL cell lines (Jurkat/ CUTLL-1) (medium picture) and T-ALL patients' blasts (bottom picture). Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., ... & Zhu, H. (2021). CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of hematology & oncology, 14(1), 1-5. |
CAR Construction : 12E7-CD28-41BB-CD3ζ Fig.3 Efcacy and specifcity of anti-CD99 CAR T cells in cell line-derived xenograft models of T-ALL. Tumor progression was monitored using bioluminescent imaging. Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., ... & Zhu, H. (2021). CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of hematology & oncology, 14(1), 1-5. |
CAR Construction : 12E7-CD28-41BB-CD3ζ Fig.4 Kaplan-Meier survival curves. Kaplan-Meier survival curves of Jurkat cell line-derived xenograft mice, MOLT-4 cell line-derived xenograft mice,nonETP ALL patient-derived xenograft mice and ETP ALL mice treated with T cells or anti-CD99 CAR T cells. Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., ... & Zhu, H. (2021). CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of hematology & oncology, 14(1), 1-5. |
CAR Construction : Fig.5 Binding kinetics of anti-CD99 scFv with CD99 protein. Analysis of the interaction between the 12E7 scFv and CD99 protein using BLItz biolayer interferometry Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., ... & Zhu, H. (2021). CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of hematology & oncology, 14(1), 1-5. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD99 (MIC2/1495R) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-CQ0323). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION